Growth • Eli Lilly
LLY
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
15,1%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
23,9%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
4,9%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
5,7%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
22,4%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
12,8%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!